<DOC>
	<DOCNO>NCT02311595</DOCNO>
	<brief_summary>The purpose study determine reduce port totally laparoscopic distal gastrectomy complete D2 lymph node dissection gastric cancer safe oncological feasible . 67 patient gastric cancer preoperative stag T1 T3 undergo reduce port totally laparoscopic distal gastrectomy . The primary end point study measure compliance rate pathology report compare previous compliance rate data .</brief_summary>
	<brief_title>A Phase II Clinical Trial Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>histologically confirm adenocarcinoma stomach Eastern Cooperative Oncology Group Eastern Cooperative Oncology Group performance status 01 , sign informed consent location primary tumor antrum , angle low body evidence distant metastasis invasion adjacent organ serosal infiltration metastatic disease previous history malignancy organ comorbidity obviate major surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>laparoscope</keyword>
</DOC>